Skip to main content

Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Publication ,  Other
Gupta, S; Halabi, S; Yang, Q; Roy, A; Tubbs, A; Gore, Y; George, DJ; Nanus, DM; Antonarakis, ES; Danila, DC; Szmulewitz, RZ; Wenstrup, R ...
March 31, 2023

<p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard model. A) The median OS in months for CTC=0 (reference), CTC+ PSMA-CTC, CTC+ PSMA+CTC but heterogeneous (<100%), and CTC+ PSMA+ 100% (homogeneous), respectively, were 25.7 (95% CI=19.8-NR), 24.5 (95% CI=16.7-30.4),15.6 (95% CI=14.4-20.7), and 35.0 (95% CI=16.9-NA). Univariate hazard ratio (HR) was 1.3 (95% CI=0.7-2.6), 2.0 (95% CI=1.0-3.8) and 0.7; 95% CI = 0.2-2.1 for CTC+, PSMA-CTC, CTC+ PSMA CTC+ but heterogeneous (<100%), and CTC+ PSMA+ 100% (homogeneous) vs. CTC=0, respectively. B) The median PFS for CTC=0 (reference), CTC+, PSMA-CTC, CTC+ PSMA+ CTC but heterogeneous (<100%), and CTC+ PSMA+ 100%, respectively, were 7.6 (95% CI=6.7-16.5), 6.0 (95% CI=3.5-11.4),5.5 (95% CI=3.6-7.6), and 5.7 (95% CI=3.0-NA). Univariate HR was 1.4 (95% CI=0.8-2.6), 2.0 (95% CI=1.1-3.6) and 1.5; 95% CI = 0.7-3.6 for CTC+, PSMA-CTC, CTC+ PSMA+ CTC but heterogeneous (<100%), and CTC+ PSMA+ 100% (homogeneous) vs. CTC=0, respectively.</p>

Duke Scholars

DOI

Publication Date

March 31, 2023
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gupta, S., Halabi, S., Yang, Q., Roy, A., Tubbs, A., Gore, Y., … Armstrong, A. J. (2023). Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. https://doi.org/10.1158/1078-0432.22438095
Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438095.
Gupta S, Halabi S, Yang Q, Roy A, Tubbs A, Gore Y, George DJ, Nanus DM, Antonarakis ES, Danila DC, Szmulewitz RZ, Wenstrup R, Armstrong AJ. Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. 2023.

DOI

Publication Date

March 31, 2023